Debio-0123 is under clinical development by Debiopharm International and currently in Phase I for Uterine Cancer. According to GlobalData, Phase I drugs for Uterine Cancer have an 80% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how Debio-0123’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Debio-0123 (ADC-730) is under development for the treatment of advanced solid tumors, glioblastoma multiforme, small-cell lung cancer and astrocytoma. The drug candidate is administered orally as a capsule. It acts by targeting WEE-1, a nuclear protein kinase. It was also under development for the treatment of colon and lung adenocarcinoma.
Debiopharm International overview
Debiopharm International, a subsidiary of Debiopharm Group, focuses on the development and manufacture of drugs for oncology and bacterial infections. The company offers oxaliplatin and triptorelin drugs. It is investigating proteins, peptides and small molecules to treat cancers, solid tumors, bone and joint infections and gastrointestinal disorders. Debiopharm is headquartered in Lausanne, Switzerland.
For a complete picture of Debio-0123’s drug-specific PTSR and LoA scores, buy the report here.